drugset / Trial / NCT06312423
Safety and Pharmacokinetics of IMT504, an Immunomodulator and Tissue Repair Inducer
Phase 1
Unknown
12 enrolled
Ministry of Public Health of the Province of La Rioja
Immunalgia Therapeutics S.A. · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
Phase 1 open-label dose-escalation study to evaluate the safety and pharmacokinetics of IMT504 Phosphorothioate Oligonucleotide, an immunomodulator and tissue repair inducer, in healthy volunteers.
Timeline
- Start
- 2024-02-23
- Primary completion
- 2024-08-30
- Completion
- 2024-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IMT504 | Oligonucleotide (other) | 20 mg | Subcutaneous |